Pennant Group Shorts at a Year High While Peers Hold Steadier Ground

PNTG carries the most short pressure among its nearest peers heading into Thursday's earnings release. Short interest has climbed to 3.5% of the free float, the highest reading in at least a year, up roughly 9% over the past month. That compares with a broadly flat week for peer median returns: ENSG fell 2.1% on the week, NHC dropped 2.1%, while UHS gained 12.4% and MD added 9.1%. PNTG lost 5.8% over the same stretch, closing at $40.00, an outlier to the downside.

The stock's own short history makes the current level stand out. Through most of September and early October, short shares held in a band around 1.1 million. From mid-October they began climbing in a steady staircase, reaching 1.22 million by October 28 before easing slightly and then pushing to a fresh high of 1.22 million on November 4. The borrow market has tightened modestly alongside that build: cost to borrow has risen 28% over the past week to 0.48%, though it remains low in absolute terms. Availability is extremely loose at 2,145% of outstanding short interest, meaning the lending pool is nowhere near exhausted and the short build reflects deliberate positioning rather than a squeeze in supply.

The analyst community is pointing the other way. Oppenheimer raised its price target to $50 from $47 on November 5, maintaining its Outperform rating just hours before the release. At $40, the stock now trades roughly 17% below the consensus target of $46.83. The bull case rests on the company's core home health and hospice business, where same-store Medicare home health admissions rose 13.6% year over year and hospice average daily census grew 10.8% in the most recent quarter, with raised full-year guidance for revenue between $1.17 billion and $1.19 billion. Bears counter that integration of former UnitedHealth/Amedisys assets could pressure margins, that Medicare reimbursement risk remains material, and that FY27 EBITDAR could come in 5% below current estimates, compressing the valuation multiple. At roughly 17.6x EV/EBITDA, the stock leaves limited room for execution shortfalls.

Retail attention has spiked ahead of the print. The ORTEX Alt Data layer shows a Wikipedia views z-score of 5.4 as of October 25, well above normal levels for this name. Separately, Goldman Sachs Asset Management added 255,716 shares in the most recent quarter to reach a 2.3% stake, while BlackRock increased its position by 243,076 shares to hold 8.5%. On the insider side, the recent activity is dominated by routine award grants to directors on October 15 and a tax-withholding transaction by the COO, neither of which signals directional conviction.

The print will test whether the operational momentum in home health and hospice, particularly margin trajectory and admission growth, is durable enough to justify the gap between the current price and where analysts have recently moved their targets.